Development of an automated platform for the optimal production of glycoconjugate vaccines expressed in Escherichia coli

Protein Glycan Coupling Technology (PGCT) uses purposely modified bacterial cells to produce recombinant glycoconjugate vaccines. This vaccine platform holds great potential in this context, namely due to its modular nature, the simplified production process in comparison to traditional chemical con...

Descripción completa

Detalles Bibliográficos
Autores principales: Samaras, Jasmin J., Mauri, Marta, Kay, Emily J., Wren, Brendan W., Micheletti, Martina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8142613/
https://www.ncbi.nlm.nih.gov/pubmed/34030723
http://dx.doi.org/10.1186/s12934-021-01588-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8142613/
https://www.ncbi.nlm.nih.gov/pubmed/34030723
http://dx.doi.org/10.1186/s12934-021-01588-1

Ejemplares similares